CU23798B6 - Combinación farmacéutica que emplea anticuerpos contra el receptor del factor de crecimiento epidérmico y agentes inmunosupresores - Google Patents

Combinación farmacéutica que emplea anticuerpos contra el receptor del factor de crecimiento epidérmico y agentes inmunosupresores

Info

Publication number
CU23798B6
CU23798B6 CU20090007A CU20090007A CU23798B6 CU 23798 B6 CU23798 B6 CU 23798B6 CU 20090007 A CU20090007 A CU 20090007A CU 20090007 A CU20090007 A CU 20090007A CU 23798 B6 CU23798 B6 CU 23798B6
Authority
CU
Cuba
Prior art keywords
receiver
growth factor
antibodies against
epidermal growth
pharmaceutical combination
Prior art date
Application number
CU20090007A
Other languages
English (en)
Other versions
CU20090007A6 (es
Inventor
Chivukula Indira Venkata
Pradip Nair
Ramakrishnan Melarkode
Casimiro Jose Enrique Montero
Rodriguez Rolando Perez
Original Assignee
Biocon Ltd
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd, Centro Inmunologia Molecular filed Critical Biocon Ltd
Publication of CU20090007A6 publication Critical patent/CU20090007A6/es
Publication of CU23798B6 publication Critical patent/CU23798B6/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporciona una combinación terapéutica de un agente inhibidor del EGFR que inhibe competitivamente la unión del EGF nativo a su receptor y un inmunosupresor para tratar un huésped mamífero, preferiblemente humano mediante la administración de una cantidad terapéuticamente efectiva del fármaco para la profilaxis y/o tratamiento de tumores. El Inmunosupresor seleccionado del grupo comprende la Rapamicina, el tacrolimus, everolimus, pimecrolimus en su forma libre o en la forma de una sal o solvatos farmecéuticamente aceptables. También se comtemplan los nuevos conjugados del anti-EGFR con fármacos, y las composiciones que contengan opcionalmente por lo menos un portador farmacéuticamente aceptable para uso simultáneo.
CU20090007A 2007-10-22 2009-01-13 Combinación farmacéutica que emplea anticuerpos contra el receptor del factor de crecimiento epidérmico y agentes inmunosupresores CU23798B6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2373CH2007 2007-10-22

Publications (2)

Publication Number Publication Date
CU20090007A6 CU20090007A6 (es) 2011-07-11
CU23798B6 true CU23798B6 (es) 2012-03-15

Family

ID=40579132

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090007A CU23798B6 (es) 2007-10-22 2009-01-13 Combinación farmacéutica que emplea anticuerpos contra el receptor del factor de crecimiento epidérmico y agentes inmunosupresores

Country Status (5)

Country Link
AR (1) AR072759A1 (es)
CU (1) CU23798B6 (es)
TW (1) TW200942260A (es)
UY (1) UY31417A1 (es)
WO (1) WO2009054001A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EA008379B1 (ru) * 2002-02-01 2007-04-27 Ариад Джин Терапьютикс, Инк. Фосфорсодержащие соединения и их применения
EP1701979A2 (en) * 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
AU2005249490B2 (en) * 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
CN103110948A (zh) * 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
EP1973576B1 (en) * 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP1996193A2 (en) * 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors

Also Published As

Publication number Publication date
TW200942260A (en) 2009-10-16
UY31417A1 (es) 2009-05-29
CU20090007A6 (es) 2011-07-11
WO2009054001A1 (en) 2009-04-30
AR072759A1 (es) 2010-09-22

Similar Documents

Publication Publication Date Title
CU23798B6 (es) Combinación farmacéutica que emplea anticuerpos contra el receptor del factor de crecimiento epidérmico y agentes inmunosupresores
AR048502A1 (es) Sinergia terapeutica de compuestos anti-cancer
AR059982A1 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
BR112016012506A2 (pt) Combinações farmacêuticas, seus usos, e uso de um portador de dados
AR079256A1 (es) Metodo para el tratamiento del cancer de mama metastasico con trastuzumab-mcc-dm1
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
UY31800A (es) Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
CY1114163T1 (el) Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR059501A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
UY31672A1 (es) "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
AR083267A1 (es) Combinaciones farmaceuticas
AR083916A1 (es) Metodo para tratar el cancer de mama y cancer de ovarios
CO6361995A2 (es) Derivados de isoquinolinona como antagonistas de nk3
RU2008148597A (ru) Фармацевтические комбинации
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
RU2014137190A (ru) Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение
RU2010123028A (ru) Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.

Legal Events

Date Code Title Description
FG Grant of patent